Blocking one of these immunomodulatory miRNAs may significantly enhance activation of cytotoxic CD8+ T cells through TCR signalling activation, which is supposed to improve the response to immunotherapy in melanoma patients. The gene discussed is CD8A; the disease is melanoma.